Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.16 is 49% above its 5-year average of -2.29, near the high end of its 5-year range (-3.70–-1.01).
1.28% above its 12-month average of -1.18.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.28.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 30 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.16
EARNINGS PER SHARE (EPS) AVG TTM
-1.18
EARNINGS PER SHARE (EPS) AVG 3Y
-1.68
EARNINGS PER SHARE (EPS) AVG 5Y
-2.29
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.28%
CURRENT VS 3Y AVG
+30.95%
CURRENT VS 5Y AVG
+49.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Annexon, Inc.
Market Cap
$688.14M
Earnings Per Share (EPS)
-1.16
TTM Avg
-1.18
3Y Avg
-1.68
5Y Avg
-2.29
Market Cap
$698.60M
Earnings Per Share (EPS)
-141.65
TTM Avg
-20.37
3Y Avg
-24.20
5Y Avg
-22.76
Market Cap
$675.41M
Earnings Per Share (EPS)
-2.72
TTM Avg
-2.70
3Y Avg
-2.77
5Y Avg
-2.61
Market Cap
$709.33M
Earnings Per Share (EPS)
1.24
TTM Avg
2.06
3Y Avg
1.25
5Y Avg
1.30
Market Cap
$719.64M
Earnings Per Share (EPS)
-1.55
TTM Avg
-1.25
3Y Avg
-1.99
5Y Avg
-2.90
Market Cap
$643.37M
Earnings Per Share (EPS)
-1.78
TTM Avg
-1.75
3Y Avg
-1.85
5Y Avg
-1.69
Market Cap
$642.31M
Earnings Per Share (EPS)
-0.88
TTM Avg
-0.85
3Y Avg
-1.91
5Y Avg
-1.52
Market Cap
$734.10M
Earnings Per Share (EPS)
-2.76
TTM Avg
-3.16
3Y Avg
-2.11
5Y Avg
-1.54
Market Cap
$637.59M
Earnings Per Share (EPS)
-2.82
TTM Avg
-1.69
3Y Avg
-1.06
5Y Avg
3.72
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $688.14M | -1.16 | -1.18 | -1.68 | -2.29 |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -141.65 | -20.37 | -24.20 | -22.76 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | -2.72 | -2.70 | -2.77 | -2.61 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 1.24 | 2.06 | 1.25 | 1.30 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -1.55 | -1.25 | -1.99 | -2.90 |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -1.78 | -1.75 | -1.85 | -1.69 |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -0.88 | -0.85 | -1.91 | -1.52 |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -2.76 | -3.16 | -2.11 | -1.54 |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -2.82 | -1.69 | -1.06 | 3.72 |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | -0.83 | -1.21 | -1.36 | -1.94 |
Trailing EPS (TTM)
$-1.16
Forward EPS (Est.)
$-1.05
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.34 |
| 2024-12-31 | -1.01 |
| 2023-12-31 | -1.77 |
| 2022-12-31 | -2.60 |
| 2021-12-31 | -3.34 |
| 2020-12-31 | -3.70 |
| 2019-12-31 | -0.97 |
| 2018-12-31 | -1.60 |
| 2017-12-31 | -0.49 |
